Product Information
Registration Status: ActiveSIN13842P
CEREZYME (IMIGLUCERASE) 400U POWDER FOR SOLUTION FOR INJECTION is approved to be sold in Singapore with effective from 2010-07-27. It is marketed by SANOFI-AVENTIS SINGAPORE PTE LTD, with the registration number of SIN13842P.
This product contains Imiglucerase 424 U in the form of INJECTION, POWDER, FOR SOLUTION. It is approved for INTRAVENOUS use.
This product is manufactured by Genzyme Corporation in UNITED STATES.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues
Indication
For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)
Mechanism of Action
Imiglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.
Clearance
* 14.5 +/- 4.0 mL/min/kg
Active Ingredient/Synonyms
Imiglucerase | Imiglucerase |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.